Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Glatiramer acetate ameliorates experimental autoimmune neuritis.
Emotional Change-Associated T Cell Mobilization at the Early Stage of a Mouse Model of Multiple Sclerosis.
B cells and multiple sclerosis.
Determination and characterization of a cannabinoid receptor in rat brain.
Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system.
Recurrent brainstem lesions mimicking infarctions in an elderly patient with neuromyelitis optica spectrum disorder.
Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis.
Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review.
The two faces of neuromyelitis optica.
Alerting Network Dysfunction in Early Multiple Sclerosis.
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis.
Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS.
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
Individual axons regulate the myelinating potential of single oligodendrocytes in vivo.
[The membrane stabilizing effect of glatiramer acetate in multiple sclerosis].
Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis.
Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects.
Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results.
Neuropathology of white matter disease in Leber's hereditary optic neuropathy.
Genzyme receives positive CHMP opinion in the European Union for once-daily, oral AUBAGIO® to treat relapsing-remitting multiple sclerosis
Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
European Commission Approves Genzyme’s Once-Daily, Oral Multiple Sclerosis Treatment Aubagio® (teriflunomide)
Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis.

Pages